...
首页> 外文期刊>Current organic chemistry >Design, Synthesis and Biopharmacological Profile Evaluation of New 2-((4-Chlorophenoxy)Methyl)-N-(Arylcarbamothioyl)Benzamides with Broad Spectrum Antifungal Activity
【24h】

Design, Synthesis and Biopharmacological Profile Evaluation of New 2-((4-Chlorophenoxy)Methyl)-N-(Arylcarbamothioyl)Benzamides with Broad Spectrum Antifungal Activity

机译:具有广谱抗真菌活性的新型2 - ((4-氯苯氧基)甲基)-N-(芳基苯胺噻唑)苯甲酰胺的设计,合成和生物发作谱评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The emerging antifungal resistance represents a major challenge for the treatment of severe fungal infections, highlighting the need to develop novel and efficient antifungal compounds. This study aimed to synthesize new title compounds and screen them for their anti fungal activity in order to generate highly accurate structure - activity relationships of 2-((4-chlorophenoxy)methyl)-N-(arylcarbamothioyl)benzamides and their de novo derivatives and to unveil some of their mechanisms of action by flow cytometry and fluorescence microscopy. The presence of functional groups was confirmed for nine new 2-((4-chlorophenoxy) methyl)-N-(arylcarbamothioyl)benzamides, using experimental and in sillco methods. The antifungal activity was assessed against a broad spectrum of 26 yeast and filamentous fungal strains, using qualitative and quantitative assays. The results showed that Candida kefyr has been the most susceptible to all tested compounds, while 1b and If induced a strong inhibitory effect on the filamentous fungi Alternaria rubi, Aspergillus ochraceus and A. niger strains growth. The derivative 1c in subinhibitory concentrations alsoincreased the susceptibility of Candida albicans clinical strains to azoles. Predicted drug likeness and pharmacokinetics profiles of most active compounds were compared with the standard antifungal ketoconazole. Furthermore, the potentially more potent 1c and if derivatives were designed and studied regarding the chemical structure-biological activity relationship and pharmacokinetics profiles versus ketoconazole. The study confirms that the new benzamide derivatives exhibited an improved pharmacokinetics profile and a good antifungal activity, acting at least by increasing membrane permeability of fungal cells. Our results are recommending them as promising candidates for the development of novel therapeutic alternatives.
机译:新出现的抗真菌抗性是治疗严重真菌感染的主要挑战,突出了开发新颖和有效的抗真菌化合物的需要。该研究旨在将新标题化合物合成并筛选它们的抗真菌活性,以产生高精度的结构 - 活性关系 - ((4-氯苯氧基)甲基)-N-(芳基霉碱噻酰)苯甲酰胺及其de Novo衍生物和它们通过流式细胞术和荧光显微镜推出它们的一些作用机制。使用实验性和Sillco方法证实了九个新的2 - ((4-氯苯氧基)甲基)-N-(Arylcarbamothioyl)苯甲酰胺的氮氧化物的存在。利用定性和定量测定,评估抗真菌活性的抗真菌活性和丝状真菌菌株的广谱和丝状真菌菌株。结果表明,念珠菌Kefyr是最容易受到所有测试化合物的影响,而1B,如果诱导对丝状真菌alertaria rubi,曲霉和A.尼格斯菌株生长的强烈抑制作用。衍生物1C在后抑制浓度的衍生物1C也增加了念珠菌蛋白患者临床菌株的敏感性。将预测的药代动力学和药代动力学与最活性化合物的药代动力学分布与标准的抗真菌酮康唑进行比较。此外,关于化学结构 - 生物活性关系和药代动力学曲线与酮康唑的设计和研究潜在的有效1c和衍生物。该研究证实,新的苯甲酰胺衍生物表现出改善的药代动力学曲线和良好的抗真菌活性,至少通过增加真菌细胞的膜渗透性来作用。我们的结果推荐它们作为开发新型治疗替代品的承诺候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号